View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 25, 2018

Mylan signs HIV test commercialisation deal with Atomo Diagnostics

Pharmaceutical company Mylan has formed a strategic alliance with medical device firm Atomo Diagnostics to boost access to HIV self-testing in low- and middle-income countries.

Pharmaceutical company Mylan has formed a strategic alliance with medical device firm Atomo Diagnostics to boost access to HIV self-testing in low- and middle-income countries.

As part of the agreement, Mylan received exclusive rights for commercialisation of in-vitro HIV rapid diagnostic tests in more than 100 countries across Africa, Asia, the Middle East, the Commonwealth of Independent States (CIS) and Latin America.

HIV testing rates have improved but expanding access to the tests is still a challenge in certain countries.

“Through the new partnership, the companies will provide all-in-one test devices, which are designed to deliver better functionality and are easy to use compared to existing multi-component rapid diagnostic tests.”

Mylan noted that offering point-of-care self-tests in community-based settings can increase the proportion of people aware of their HIV status, in turn enabling treatment or prevention.

Through the new partnership, the companies will provide all-in-one test devices, which are designed to deliver better functionality and are easy to use compared to existing multi-component rapid diagnostic tests.

Mylan CEO Heather Bresch said: “Our partnership with Atomo to supply HIV rapid diagnostic tests for self-testing is an important step in our collective goal of preventing HIV infections and expanding treatment.”

HIV Self Test by Atomo Diagnostics secured the European CE-Mark in October last year. The test is a qualitative immunoassay designed to detect antibodies to HIV type 1 and type 2 in human whole blood.

Atomo Diagnostics founder and CEO John Kelly said: “This strategic partnership will mean that the products designed by Atomo can be introduced to more than 100 countries, so that millions of people will have access to award-winning rapid tests.

“We believe that Mylan is the ideal partner to ensure that our HIV self-test products have maximum impact in the fight against HIV/AIDS.”

Mylan intends to globally launch the Mylan HIV Self-Test early next year.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network